Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Pierre Sié"'
Publikováno v:
Journal of Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis, Wiley, 2018, 16 (5), pp.1017-1019
Journal of Thrombosis and Haemostasis, 2018, 16 (5), pp.1017-1019
Journal of Thrombosis and Haemostasis, Wiley, 2018, 16 (5), pp.1017-1019
Journal of Thrombosis and Haemostasis, 2018, 16 (5), pp.1017-1019
International audience
Autor:
Pierre Sié
Publikováno v:
La Presse Médicale. 44:772-778
Routine clotting time assays (Prothrombin Time/INR, activated Partial Thromboplastin Time [aPTT]) are prolonged at variable extent by direct oral anticoagulants (DOAC), according to the assay, the reagent and the type of DOAC. These assays are not re
Autor:
Pierre Sié, Isabelle Gouin-Thibault, Emmanuel Touzé, Laurent Derex, S. Susen, E. de Maistre, Yves Gruel
Publikováno v:
European journal of neurology. 25(5)
BACKGROUND AND PURPOSE Whereas intravenous thrombolysis (IVT) is allowed for acute ischaemic stroke in patients on vitamin K antagonists with international normalized ratio ≤1.7, there are no similar recommendations for patients on direct oral anti
Autor:
Groupe d’intérêt en hémostase péri-opératoire, Gilles Pernod, Pierre Sié, Pierre Albaladejo, Charles-Marc Samama
Publikováno v:
La Presse Médicale. 43:637-644
New oral anticoagulants do represent a major step forward as compared to low molecular weight heparins and vitamin K antagonists. Several issues deserve attention regarding their perioperative management. Three (and very soon four or five) active mol
Autor:
Nicholas Moore, Mathieu Fiore, Paquita Nurden, Xavier Pillois, Pierre Sié, Simon Lorrain, Jean-François Viallard, M.-A. Bernard
Publikováno v:
Platelets. 27(6)
Inherited thrombocytopenia (IT) is a heterogeneous group of rare diseases that are often confused with immune thrombocytopenia (ITP). The objective of this study was to supply clinicobiological elements that allow a distinction to be drawn between IT
Publikováno v:
Blood Coagulation & Fibrinolysis. 14:505-511
To improve the standardization of the factor VII clotting activity (FVII:C) assay in patients treated with recombinant activated factor VII (rFVIIa), we conducted a multicentre study on plasma samples from four patients with haemophilia A, before and
Autor:
Normand Blais, Meyer Michel Samama, Sophie Susen, Patrick Mismetti, Juan V. Llau, Ariel Cohen, Anne Godier, Yves Gruel, Emmanuel de Maistre, Pierre Sié, Gilles Pernod, Nadia Rosencher, Charles Marc Samama, Pierre Fontana, P. Albaladejo, Jean-François Schved
Publikováno v:
Archives of Cardiovascular Diseases, Vol. 106, No 6-7 (2013) pp. 382-93
Direct new oral anticoagulants (NOACs) - inhibitors of thrombin or factor Xa - are intended to be used largely in the treatment of venous thromboembolic disease or the prevention of systematic embolism in atrial fibrillation, instead of vitamin K ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bba67768790f9af12e0bb2f18afa6ea3
https://archive-ouverte.unige.ch/unige:29636
https://archive-ouverte.unige.ch/unige:29636
Autor:
Thibault Lhermusier, Sophie Voisin, Vanina Bongard, Didier Carrié, Pierre Sié, Mohammed Amir Tidjane
Publikováno v:
Thrombosis and haemostasis. 106(2)
SummaryThe results of the whole blood VerifyNow® P2Y12 assay can be expressed as platelet reaction units (PRU) or % inhibition index (%inh), but an optimal cut-off for the assessment of high on-treatment platelet reactivity (HPR) predictive of clini
Publikováno v:
Thrombosis and haemostasis. 95(4)
SummaryActivated protein C resistance (APCR), measured using the original assay described by Dahlbäck, is a risk factor for venous thrombosis independent of the factor V Leiden (FVL) mutation. This assay is based on the activated partial thromboplas